Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA was delisted on the 25th of September, 2023.
194 hedge funds and large institutions have $3.75B invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2021 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 69 increasing their positions, 66 reducing their positions, and 40 closing their positions.
75% more funds holding in top 10
Funds holding in top 10: 4 → 7 (+3)
49% more capital invested
Capital invested by funds: $2.52B → $3.75B (+$1.23B)
5% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 66
3% less funds holding
Funds holding: 201 → 194 (-7)
15% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 40
44% less call options, than puts
Call options by funds: $30.4M | Put options by funds: $54.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$85.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$77.8M |
| 3 |
BlackRock
New York
|
+$73.6M |
| 4 |
State Street
Boston,
Massachusetts
|
+$23.6M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$17.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$28.5M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$26.2M |
| 3 |
Goldman Sachs
New York
|
-$19.2M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$18M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$17.9M |
RETA Hedge Fund Activity: Q2 2021 in Review
194 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) for Q2 2021, worth a combined $3.75B — up 49% from $2.52B a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of RETA and 34 opened new positions — a net loss of 6 holders — while 66 trimmed existing stakes and 69 added.
The largest buyer was Invesco, adding an estimated $85.1M. The largest seller was Pictet Asset Management (UK), cutting an estimated $28.5M.
- 194 institutional investors held Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) as of Q2 2021, down from 201 in Q1 2021.
- Funds reported $3.75B of Reata Pharmaceuticals, Inc. Class A Common Stock stock for Q2 2021, up 49% quarter-over-quarter.
- 34 funds opened new Reata Pharmaceuticals, Inc. Class A Common Stock positions in Q2 2021 and 40 closed out, a net change of -6 holders.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock buyer in Q2 2021 was Invesco, an estimated $85.1M added.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock seller in Q2 2021 was Pictet Asset Management (UK), an estimated $28.5M sold.
Based on aggregated 13F filings for Q2 2021.